P

PUSZTAI L.

Last name: PUSZTAI L.

2021 (v1)

Publication

Metadata-only

Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis

Schettini F. Giuliano M. Giudici F.

A precise assessment of the efficacy of first‐/second‐line endocrine therapies (ET) ± target therapies (TT) in clinically‐relevant subgroups of hormone receptor‐positive (HR+)/HER2‐negative metastatic breast cancer (MBC) has not yet been conducted. To improve our current knowledge and support clinical decision‐making, we thus conducted a...

Uploaded on: April 14, 2023
2021 (v1)

Publication

Metadata-only

Expected medium- And long-term impact of the COVID-19 outbreak in oncology

Onesti C. E. Tagliamento M. Curigliano G.

No description

Uploaded on: February 11, 2024
2023 (v1)

Publication

Metadata-only

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer

Lambertini M. Ceppi M. Anderson R. A.

BACKGROUND: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment-induced gonadotoxicity. PATIENTS AND METHODS: The present biomarker analysis of...

Uploaded on: February 7, 2024